What is Neurapheresis™ Therapy?
The Neurapheresis™ Cerebrospinal Fluid (CSF) Treatment Platform is being developed to provide a safe, device-based alternative for treating debilitating and life-threatening diseases that involve foreign bodies in the cerebrospinal fluid.
The current Neurapheresis platform offers a tailored process for the treatment and return of cerebrospinal fluid. Neurapheresis Therapy in post-subarachnoid hemorrhage (aSAH) patients is presently being utilized in the PILLAR Feasibility Trial in the US. The trial is intended to rapidly remove red blood cells (RBCs) and hemoglobin from the CSF shortly after SAH securement. The removal of RBCs and their released cytotoxic byproducts may be accomplished much more efficiently with Neurapheresis therapy, than with standard gravity-dependent drains. It is theorized that early, rapid removal of RBCs post-SAH may reduce downstream complications including the incidence of hydrocephalus, cerebral vasospasm, and contribute to a shorter length of stay, lower healthcare resource utilization, improved clinical functional outcomes, and a reduced overall healthcare economic burden.1
This short video explains the Neurapheresis therapy process for the removal, treatment and return of CSF.
1Bardutzky J et al. EARLYDRAIN- Outcome after Early Lumbar CSF-Drainage in Aneurysmal Subarachnoid Hemorrhage: Study Protocol for a Randomized Controlled Trial. Trials 12 (2011):203.